Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2017 04:38 ET | Source: Neuralstem, Inc.

Neuralstem宣佈最後一名受試者登記加入用於治療重度抑鬱症的NSI-189的II期臨床試驗

- 目前預期II期數據將較原定計劃提前於2017年第三季度獲得馬里蘭州日耳曼敦, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...
February 17, 2017 04:38 ET | Source: Neuralstem, Inc.

Neuralstem宣布最后一名受试者登记加入用于治疗重度抑郁症的NSI-189的II期临床试验

- 目前预期II期数据将较原定计划提前于2017年第三季度获得马里兰州日耳曼敦, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...
February 17, 2017 04:38 ET | Source: Neuralstem, Inc.

뉴럴스템, 주요우울장애 치료 신약인 NSI-189의 임상2상시험 대상자 모집 완료

당초 예상보다 빠른 올해 3분기에 임상2상 결과 나올 예정-미국 메릴랜드주 저먼타운, Feb. 17, 2017 (GLOBE NEWSWIRE) -- 바이오 제약사인 뉴럴스템(Neuralstem, Inc.)(나스닥 거래명: CUR)이 주요우울장애(MDD) 치료제인 NSI-189의 임상2상시험 대상자 모집을 마무리했다. NSI-189는 뉴럴스템의 신약으로...
February 17, 2017 04:38 ET | Source: Neuralstem, Inc.

Neuralstem Mengumumkan Subjek Terakhir Sertakan dalam Percubaan Fasa 2 dengan NSI-189 untuk Kecelaruan Kemurungan Major

- Data Fasa 2 Kini Dijangka Awal Daripada Yang Dijadualkan dalam Suku 3 2017 -GERMANTOWN, Md., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), sebuah syarikat biofarmaseutikal yang...
February 16, 2017 07:02 ET | Source: Neuralstem, Inc.

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
February 13, 2017 06:58 ET | Source: Neuralstem, Inc.

Neuralstem to Present at BIO CEO & Investor Conference

GERMANTOWN, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
January 06, 2017 13:01 ET | Source: Neuralstem, Inc.

Neuralstem Announces a 1-for-13 Reverse Stock Split

GERMANTOWN, Md., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
December 12, 2016 14:36 ET | Source: Neuralstem, Inc.

Neuralstem宣布Tianjin Pharmaceutical Group International Holdings Co., LTD.完成对其20,000,000美元的战略性投资交易

美国马里兰州日耳曼敦, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc.（纳斯达克：CUR）宣布Tianjin Pharmaceutical Group International Holdings Co., LTD.（TJPH或Tianjin）完成对其20,000,000美元的战略性投资交易。Neuralstem,...
December 12, 2016 07:38 ET | Source: Neuralstem, Inc.

Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.

GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
November 08, 2016 07:35 ET | Source: Neuralstem, Inc.

Neuralstem Reports Third Quarter 2016 Results

GERMANTOWN, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...